| Size | Price | Stock | Qty |
|---|---|---|---|
| 100mg |
|
||
| Other Sizes |
| Targets |
Plasmodium
mPEG-DSPE (MW 2000) sodium does not target a biological receptor. It is an amphiphilic polymer-lipid conjugate used as a biomaterial in nanomedicine. Its mechanism is physicochemical rather than pharmacological: the DSPE lipid tail embeds into lipid bilayers while the PEG chain extends into the aqueous environment, providing steric stabilization and reducing opsonization. |
|---|---|
| ln Vitro |
mPEG-DSPE is not a drug and has no intrinsic pharmacological activity. As an excipient in liposome formulations, it enhances liposome stability, prolongs circulation time by reducing uptake by the reticuloendothelial system (RES), increases hydrophilicity of liposome surfaces, and improves the solubility and pharmacokinetic properties of encapsulated drugs.
|
| ln Vivo |
Not applicable. mPEG-DSPE is an excipient, not a therapeutic agent. In liposome formulations, it improves the in vivo performance of encapsulated drugs by extending circulation half-life and enhancing tumor accumulation via the enhanced permeability and retention (EPR) effect. It is used in the research of anti-cancer and anti-malarial active molecules.
|
| Enzyme Assay |
Not applicable. mPEG-DSPE is not used in enzyme/receptor binding assays. Its utility as a formulation component is assessed by its ability to form stable liposomes, measured by dynamic light scattering (DLS) for size and polydispersity, zeta potential for surface charge, and encapsulation efficiency of a model drug.
|
| Cell Assay |
mPEG-DSPE is not used in cell-based assays as a test article. Its biocompatibility can be assessed by incubating liposomes containing mPEG-DSPE with cell lines (e.g., HEK293, HeLa) and measuring cell viability by MTT assay (typical range: 0.1-10 mg/mL). Low cytotoxicity indicates good biocompatibility for drug delivery applications.
|
| Animal Protocol |
For in vivo studies, mPEG-DSPE is formulated into liposomes containing a therapeutic payload (e.g., doxorubicin or paclitaxel). The liposomes are administered intravenously to tumor-bearing mice (e.g., 5-50 mg/kg of lipid). Blood samples are collected at various time points (5 min to 48 hours) to measure drug concentration by LC-MS. Prolonged circulation half-life (e.g., from hours to >24 hours) compared to free drug or non-PEGylated liposomes demonstrates the stealth effect of mPEG-DSPE.
|
| ADME/Pharmacokinetics |
mPEG-DSPE (MW 2000) sodium has an average molecular weight of 2000 (PEG chain) plus the DSPE lipid portion. It is a white to off-white solid at room temperature with purity ≥99%. It is soluble in organic solvents (chloroform, methanol) and can be used to prepare liposomes by thin-film hydration or ethanol injection methods. It is stable when stored at -20degC under inert atmosphere.
|
| Toxicity/Toxicokinetics |
mPEG-DSPE is generally recognized as a biocompatible and biodegradable material with low toxicity. The PEG segment is non-toxic and eliminated renally, while the DSPE lipid is metabolized to endogenous phospholipids. At typical formulation concentrations (1-20 mol% of total lipids), it is well-tolerated in animal studies. No significant toxicity has been reported for mPEG-DSPE itself.
|
| References |
[1]. Rathore SS, et al. Effect of surface charge and density of distearylphosphatidylethanolamine-mPEG-2000 (DSPE-mPEG-2000) on the cytotoxicity of liposome-entrapped ricin: effect of lysosomotropic agents. Int J Pharm. 2008;350(1-2):79-94.
[2]. Hasan GM, et al. Inhibition of the Growth of Plasmodium falciparum in Culture by Stearylamine-Phosphatidylcholine Liposomes. J Parasitol Res. 2011;2011:120462. |
| Additional Infomation |
mPEG-DSPE (MW 2000) sodium is a research-grade phospholipid-PEG conjugate used as an excipient in liposome drug delivery systems. It is widely used for preparing stealth liposomes that evade RES clearance, enabling prolonged circulation and enhanced tumor targeting. It is also a component in FDA-approved liposomal drugs (e.g., Doxil/Caelyx). This product is for laboratory research use and not for human therapeutic administration.
|
| Molecular Weight |
2000(Average)
|
|---|---|
| Related CAS # |
mPEG-DSPE (MW 2000);147867-65-0
|
| Appearance |
Typically exists as solid at room temperature
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO :~12.5 mg/mL
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
